Objectives: To evaluate the literature describing the spectrum of MRI lesions in axSpA and to generate a consensus update on standardized definitions.

Methods: The literature pertaining to MRI lesion definitions in axSpA was discussed at 3 meetings of the ASAS MRI group attended by 26 investigators. The group reviewed the literature for MRI lesion definitions and decided by consensus which definitions would be retained, which required modification, and which required a new definition.

Results: For definitions denoting signs of activity in the SIJ, there are no revisions to the most current ASAS definition of a positive MRI. Definitions for capsulitis and enthesis are revised. A new definition, joint space enhancement, denotes increased signal on contrast-enhanced images in the joint space of the cartilaginous portion of the SIJ. This replaces the term ‘synovitis’ and a separate definition describes what constitutes joint space fluid. For structural change in the SIJ, the definition for sclerosis is unchanged. Revised definition for a fatty lesion incorporates characteristics typical of axSpA, and for erosion requires both loss of cortical bone as well as adjacent marrow matrix. A new definition, fat metaplasia in the joint space (‘backfill’), denotes the reparative change on a T1 image at the site of erosion when signs of activity recede. The new definition for ankylosis stresses the continuity of bright marrow signal across the joint space. Spinal lesion definitions are divided into those that occur in defined central and lateral sagittal slices. The revised definition of a vertebral corner inflammatory lesion divides this into a regular (type A) and dimorphic (type B) lesion. A new definition for corner erosion requires both loss of cortical bone as well as adjacent marrow matrix. New definitions for new bone growth require bright signal on T1 images extending from the vertebral corner marrow or endplate, which may (ankylosis) or may not (bone spur) be continuous with the adjacent vertebral.

Conclusions: The ASAS MRI group has generated a consensus based update on MRI lesions in axSpA.

REFERENCES:

Disclosure of Interest: None declared

THU0277
WHICH MRI LESIONS IN THE SACROILIAC JOINT ARE ASSOCIATED WITH THE DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS AFTER 2 YEARS FOLLOW UP IN THE ECHOGRAPHY IN SPONDYLOARTHRITIS COHORT (ECHOSPA)?

W.P. Makowskowycz1, D. Loeuille2, S. Wichuk1, J. Paschek1, O. Judet1, M. Breban5, M.-A. D'Agostino3, R.G. Lambert1. 1Medicine, University of Alberta, Edmonton, Canada; 2Rheumatology, CHU Vaudreuil les Nancy, Nancy, France; 3CARe Arthritis, Edmonton, Canada; 4Radiology; 5Rheumatology, Ambroise Paré Hospital, Boulogne-Billancourt, France; 5Radiology, University of Alberta, Edmonton, Canada

Background: MRI of the sacroiliac joint (SIJ) is emerging as an important prognostic tool for patients presenting with SIJ and this may have consequences for early treatment. A major challenge in early SA is establishing the diagnosis and this requires prospective follow up to determine which cases have developed SA with more certainty. In addition, it is unclear which MRI lesions have prognostic capacity.

Objectives: To assess the baseline distribution and prognostic capacity of MRI lesions in the SIJ of patients diagnosed with axSpA after 2 years follow up in the ECHOSPA cohort.

Methods: Consecutive outpatients with age <50 years and symptoms >3 months suggestive of SpA (inflammatory back pain, peripheral arthritis or inflammatory arthralgia, enthesitis or dactylitis, uveitis with B27 positivity, a family history of SpA) were enrolled in the prospective French ECHOSPA cohort study. The diagnosis of SpA was ascertained by an expert committee, blind to MRI evaluation, among patients fulfilling the ASAS criteria. Among them, 211 patients have had a mSASSS scoring at least 2 units of the mSASSS 2 years after the inclusion.

Conclusions: Assessment of both active and structural lesions on MRI may help determine which patients have axSpA with higher diagnostic certainty over time.


THU0278
SERUM CALPROTECTIN IS CORRELATED WITH DISEASE ACTIVITY IN EARLY AXIAL SPONDYLOARTHRITIS BUT DOES NOT PREDICT RADIOGRAPHIC PROGRESSION AT 2 YEARS: RESULTS FROM THE DESIR COHORT

X. Romand1, M.H. Paclet2, A. Courtier2, M.-V.-C. Nguyen1, F. Berenbaum1, D. Wendling2, P. Gaudin1, A. Baillet1. 1Rheumatology, CHU Grenoble Alpes Hôpital Sud, Université Grenoble Alpes, GREPI, EA7408, Echirons; 2Biology, CHU Grenoble Alpes, GREPI, EA7408; 3Sinnovlab, 4Sinnovlab, GREPI, EA7408, Université Grenoble Alpes, Grenoble; 5Rheumatology, Sorbonne Université, INSERM, DHU 2b3, AP-HP Hôpital Saint-Antoine, Paris; 6Rheumatology, University Teaching Hospital CHRU Besançon, Besançon, France

Background: Calprotectin (S100A8/A9), a protein secreted by activated neutrophils and monocytes in inflammatory conditions, is upregulated in active spondyloarthritides and associated with radiographic spinal progression in axial spondyloarthritis (axSpA).

Objectives: To determine if serum calprotectin level at baseline can predict the radiographic progression of structural damage in spine at 2 years in the early axSpA cohort DESIR (Devenir des Spondyloarthrites Indifférenciées Récentes) and to compare the association with spine and sacroiliac joint (SIJ) inflammation on magnetic resonance imaging (MRI).

Methods: Patients presenting with inflammatory back pain suggestive of axSpA for less than 3 years from the DESIR cohort were analysed. axSpA patient were defined as patients who fulfilled the Assessment in SpondyloArthritis Society (ASAS) criteria for axSpA at baseline. Calprotectin was assessed in the serum at baseline with ELISA kit (HyCuIt Biotech, the Netherlands). Spine radiographs, SIJ and spine MRI were centrally scored. Radiographic spinal progression was defined as worsening by ≥ 2 units of the mSASSS 2 years after the inclusion. Level of MRI spine and SIJ inflammation at baseline and 2 years was evaluated with the Berlin and SPARCC score. The associations between calprotectin level and mSASSS worsening were tested with Wilcoxon test, Berlin and SPARCC score were tested by Spearman’s correlation tests.

Results: Of all, 426 had a calprotectin dosage and an early axSpA according to the ASAS criteria. Among them, 212 patients have a mSASSS scoring at baseline and M24. A total of 399 patients had had spinal and SIJ MRI scoring at baseline. Only 15 patients had a radiographic progression with a variation of mSASSS ≥ 2. We showed a correlation between baseline calprotectin and MRI inflammation in SIJ or spine (Berlin score (r=0.15, p=0.003), SPARCC Sacroiliac score (r=0.12, p=0.012) and SPARCC Spine score (r=0.16, p=0.002)). Calprotectin baseline level was significantly higher in patients who fulfilled axSpA ASAS sacroiliitis arm criteria versus those who fulfilled ASAS HLA-B27 arm criteria with- out any signs of sacroilitis or versus patients that did not fulfil ASAS criteria

Conclusions: Of all, 426 had a calprotectin dosage and an early axSpA according to the ASAS criteria. Among them, 212 patients have a mSASSS scoring at baseline and M24. A total of 399 patients had had spinal and SIJ MRI scoring at baseline. Only 15 patients had a radiographic progression with a variation of mSASSS ≥ 2. We showed a correlation between baseline calprotectin and MRI inflammation in SIJ or spine (Berlin score (r=0.15, p=0.003), SPARCC Sacroiliac score (r=0.12, p=0.012) and SPARCC Spine score (r=0.16, p=0.002)). Calprotectin baseline level was significantly higher in patients who fulfilled axSpA ASAS sacroiliitis arm criteria versus those who fulfilled ASAS HLA-B27 arm criteria without any signs of sacroilitis or versus patients that did not fulfil ASAS criteria.


Downloaded from http://ard.bmj.com/ on September 16, 2023 by guest. Protected by copyright.
GENDER DIFFERENCE IN PSYCHOLOGICAL STATUS EARLY AND LONG-TERM TREATMENT RESPONSE AS patients. Clini-
sions, while female patients are more likely to have psychological disorders. Clin-

Conclusions: Calprotectin do not seem to be a helpful biomarker predicting clini-
cally relevant radiographic progression at 2 years although calprotectin levels at baseline are moderately correlated with disease activity in early axSpA.


THU0279 GENDER DIFFERENCE IN PSYCHOLOGICAL STATUS AND SLEEP QUALITY IN THE PATIENTS WITH ANKYLOSING SPONDYLITIS

Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease which mainly involves the spine and sacroiliac joints. Anxiety and depression, are common among people with arthritis and interplay independently and synergisti-
cally with clinical outcomes such as pain and disability. Psychological variables can be found either within the body functions or within the personal factors. Mean-
while, AS patients may suffer from various sleep problems. Pain intensity, anxiety,

Results: Totally 3117 patients were included in the study. 2501 were males, 616 were female patients.' whose mean age were 27.20±9.13 years. While 616 were female patients whose mean age were 28.84±9.21 years. 32.3% of the patients had anxiety. 62.2% had depression according to SDS. 63.4% had sleep disturbance. Male patients had an earlier age of disease onset than females (p<0.01). Although female patients had a shorter disease duration, they had higher scores of SAS and SDS (p<0.05). There was no significant difference in sleep quality between male and female patients.

Conclusions: A large number of AS patients were found to have anxiety, depres-
sion, sleep disturbance. Male AS patients tend to have an earlier age of disease onset while female patients are more likely to have psychological disorders. Clin-
icians should take these factors into account during the assessment of the patients.

REFERENCES: [1] McWilliams L A, Cox BJ and Enns MW. Mood and anxiety disorders asso-


THU0280 EARLY AND LONG-TERM TREATMENT RESPONSE AS WELL AS HIGH TOLERABILITY LEAD TO HIGH TREATMENT SATISFACTION OF A THERAPY WITH USTEKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS – RESULTS OF THE NON-INTERVENTIONAL STUDY SUSTAIN


Background: SUSTAIN is a prospective, multi-centre non-interventional study in Germany to observe long term efficacy and safety, quality of life and further patient reported outcomes in patients with active psoriatic arthritis under treatment with ustekinumab in routine clinical care.

Methods: In this study nearly 400 patients were planned to be documented at 75 centres for 160 weeks with documentation intervals at week 0 and 4 and then every 12 weeks. The treatment with Ustekinumab is according to the label (Ste-
lar®). Besides demographic data, the following data will be documented: Number of swollen and tender joints, tender entheses, amount of skin symptoms (BSA and PASI), patient reported outcome concerning disease activity and pain, Health Assessment Questionnaire (HAQ), quality of life (SF-12), sleep quality (VAS), satis-

Results: For the present analysis 336 patients (57% women) at 75 centres were observed. The visit at week 4 was documented for 290 patients, at week 16 for 305 patients, at week 28 for 262 patients, and at week 76 for 100 patients. At baseline, the patients had a mean age of 54 years and BMI of 30 kg/m². 53.9% of the patients had as prior medication a TNF inhibitor and stopped because of inadequate response. Only 38% of the patients used MTX as concom-

Conclusions: The non-interventional study SUSTAIN showed relevant improve-
ments with high therapy satisfaction and good safety in patients with active psoriatic arthritis under treatment with ustekinumab in routine clinical care.

Disclosure of Interest: All other authors have declared no conflicts of interest.

THU0223 Minimal Disease Activity – A new outcome measure of therapy response in patients with psoriatic arthritis